Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$89.90+0.13%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · EW
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 7.1% |
| Our one-year growth estimate | diamond | 10.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 3.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers
EW — President transition
Dated 2026-08-28
Corporate Vice President — Donald E. Bobo, Jr.: The filing discloses a planned retirement of a Corporate Vice President with a defined transition period and consulting arrangement, indicating an orderly succession rather than a sudden loss of executive leadership.
Why it matters: The new CFO's plans could influence Edwards' financial strategy and growth outlook.
Watch forThe new CFO announces a clear strategic plan that aligns with growth goals.
Also watch forThe new CFO's initiatives are vague or do not align with growth expectations.
Why it matters: An update on TAVR sales growth guidance will show how well Edwards is expanding its market share.
Supportive ifManagement raises TAVR sales growth guidance above 9% for 2026.
Worry ifTAVR sales growth guidance remains at or below 8% for 2026.
Why it matters: The new CFO may bring changes to financial management and strategy. This could affect growth and investment plans.
Watch forThe financial strategy is improving after the CFO change.
Also watch forThere are no big changes or problems with the financial strategy after the change.
Why it matters: Results from the PROGRESS trial could influence clinical practices and drive TAVR adoption.
Watch forThe PROGRESS trial shows big benefits for TAVR in patients with moderate aortic stenosis.
Also watch forThe PROGRESS trial shows no big benefits for TAVR in patients with moderate aortic stenosis.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$87 on $10,000 · ±0.9% | How much price usually moves either way. |
| Bad day | $244 loss on $10,000 · 2.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,319 loss on $10,000 · 13.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Strong TMTT sales growth shows new therapies are being adopted. This means market expansion.
Supportive ifTMTT sales reported above $780 million for 2026.
Worry ifTMTT sales reported below $760 million for 2026.
Why it matters: Approval would add to Edwards' products. It would also improve their position in tricuspid care.
Supportive ifFDA may approve the PASCAL tricuspid use in Q4.
Worry ifApproval for the PASCAL tricuspid use is delayed or denied.
Why it matters: Closing this $4.2 billion sale will boost Edwards' financial flexibility for growth. It signals a focus on structural heart disease.
Supportive ifThe deal will close by the end of 2024. All regulatory approvals will be obtained.
Worry ifThe transaction fails to close or is delayed significantly beyond 2024.
Why it matters: Results from this trial could impact clinical practices and boost TAVR adoption.
Watch forPositive results from the PROGRESS trial presented at TCT.
Also watch forNegative results or unclear data from the PROGRESS trial.
Why it matters: The decision could help more Medicare patients get TAVR therapy. This would affect sales.
Supportive ifCMS announces a favorable decision on the TAVR NCD.
Worry ifCMS makes a bad decision on the TAVR NCD.